RecruitingPhase 2NCT07704164

Colchicine to Reduce Coronary Artery Inflammation in People With HIV

A Randomised, Double-Blind, Multicenter, Placebo-Controlled Clinical Trial of Colchicine to Reduce Coronary Artery Inflammation in People With HIV. COLCOHIV

Sponsor

Instituto de Investigación Hospital Universitario La Paz

Enrollment

90 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

HIV Infection Cardiovascular Diseases (CVD)

Summary

The purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clinical trial. Neither participants nor researchers will know which treatment is assigned during the study. The primary endpoint is the change in coronary artery inflammation measured by coronary computed tomography angiography (CCTA) after 96 weeks.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Colchicine 0.5 mg and a drug called Placebo for people with cardiovascular diseases (cvd) and hiv infection. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine 0.5 mg

Colchicine 0.5 mg administered orally once daily for 96 weeks as an anti-inflammatory treatment to reduce coronary artery inflammation in people living with HIV and high cardiovascular risk.

DRUGPlacebo

Matching placebo administered orally once daily for 96 weeks.